Dr. Tam Discusses BTK Inhibition in CLL

Constantine S. Tam, MD
Published: Thursday, Feb 02, 2017



Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses BTK inhibition in chronic lymphocytic leukemia (CLL).

In a dose-escalation study, the BTK inhibitor ibrutinib (Imbruvica) was explored in patients with CLL. Most of the current available agents aren’t selective enough and have not exploited the full potential of BTK inhibition in CLL, says Tam.

Remission rates has been observed at 34% in patients with Waldenström's macroglobulinemia when BTK inhibition has been pushed with higher rates of ibrutinib. By increasing the level of BTK inhibition, remission rates have more than doubled in patients.
 


Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses BTK inhibition in chronic lymphocytic leukemia (CLL).

In a dose-escalation study, the BTK inhibitor ibrutinib (Imbruvica) was explored in patients with CLL. Most of the current available agents aren’t selective enough and have not exploited the full potential of BTK inhibition in CLL, says Tam.

Remission rates has been observed at 34% in patients with Waldenström's macroglobulinemia when BTK inhibition has been pushed with higher rates of ibrutinib. By increasing the level of BTK inhibition, remission rates have more than doubled in patients.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x